GlassScriptPhysician profile
Kathryn Kizzar
NPI 1912463589
$1,924.69
in general payments reported to CMS, 2019-2025
19 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $129 · 2023: $613 · 2024: $160 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $503.71 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $383.96 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $167.64 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $124.97 | 2023 | |
| Janssen Pharmaceuticals, INC | $112.39 | 2021-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $110.26 | 2021 | |
| Pfizer INC. | $93.93 | 2023-2025 | |
| Amgen INC. | $77.72 | 2021-2023 | Repatha, Otezla |
| Bausch Health US, LLC | $69.71 | 2021 | |
| Cranial Technologies, INC | $49.40 | 2022-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $38.53 | 2023-2025 | Farxiga, Breztri |
| Gilead Sciences, INC. | $35.52 | 2025 | |
| Glaxosmithkline, LLC. | $29.28 | 2023 | Arexvy |
| Sumitomo Pharma America, INC. | $27.28 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $23.55 | 2023 | Thinprep 2000 Processor, Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.00 | 2025 | Ofev |
| Amarin Pharma, INC. | $20.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.14 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $15.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Kizzar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.